Pleural empyema medical therapy

Jump to navigation Jump to search

Empyema Main Page

Pleural empyema Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pleural empyema from other Diseases

Epidemiology and Demographics

Screening

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

ECG

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pleural empyema medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pleural empyema medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pleural empyema medical therapy

CDC on Pleural empyema medical therapy

Pleural empyema medical therapy in the news

Blogs on Pleural empyema medical therapy

Directions to Hospitals Treating Pleural empyema

Risk calculators and risk factors for Pleural empyema medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Medical Therapy

Definitive treatment for empyema entails drainage of the infected pleural fluid. A chest tube may be inserted, often using ultrasound guidance. Intravenous antibiotics are given. If this is insufficient, surgical debridement of the pleural space may be required.

Antibiotic Therapy

Following are the guidelines to treat Pleural empyema .

▸ Click on the following categories to expand treatment regimens.

Pleural Empyema

  ▸   Neonates

  ▸   Infants/Children

  ▸   Adult

Neonates
Preferred Regimen
Age 0-7 days and Weight ≤ 2000 gm
If MSSA
Nafcillin 25 mg/kg IV q12h
OR
Oxacillin 25 mg/kg IV q12h
If MRSA
Vancomycin 12.5 mg/kg IV q12h
Age 7-28 days and Weight ≤ 2000 gm
If MSSA
Nafcillin 25 mg/kg q8h
OR
Oxacillin 25 mg/kg IV q12h
If MRSA
Vancomycin 15 mg/kg IV q12h
Age 0-7 days and Weight > 2000 gm
If MSSA
Nafcillin 25 mg/kg q8h
OR
Oxacillin 25 mg/kg IV q12h
If MRSA
Vancomycin 18 mg/kg IV q12h
Age 7-28 days and Weight > 2000 gm
If MSSA
Nafcillin37 mg/kg q6h
OR
'Oxacillin 37 mg/kg q6h
If MRSA
Vancomycin 22 mg/kg q12h
Infants/Children
Preferred Regimen
Cefotaxime 100 mg/kg IV q8h
OR
Ceftriaxone 100 mg/kg IV q24h
'If MSSA
Vancomycin 40 mg/kg/day IV in 3-4 divided doses
With or Without
'Cefotaxime 100 mg/kg IV q8h
OR
Ceftriaxone 100 mg/kg IV q24h
If H.Influenzae suspected
Adult
Preferred Regimen
For Strep. pneumoniae or Streptococcus sp (Group A)
Cefotaxime 2 gm IV q8h
OR
Ceftriaxone 2 gm IV q24h or Penicillin 12-18 million units IV divided q4h/day
OR
Ampicillin 8-12 gm IV divided q4h/day
For Staph. aureus
MSSA
Nafcillin2 gm IV q4h
OR
Oxacillin 2 gm IV q4h
MRSA
Vancomycin 10-15 mg/kg IV q8-12h
OR
Linezolid 600 mg IV q12h
For H. influenzae
Ceftriaxone 2 gm IV q24h
Subacute/Chronic
Clindamycin 450-900 mg IV q8h
PLUS
'Ceftriaxone 2 gm IV q24h
Alternative Regimens
For Strep. pneumoniae or Streptococcus sp (Group A)
Vancomycin 1 gm IV q12h
For H. influenzae
TMP-SMX (5-10 mg/kg/day as trimethoprim component) IV/po in 2-3 divided doses
OR
Ampicillin Sulbactam 3 gm IV q6h (child dose 100-300 mg/kg/day IV divided q6h)
Chronic
Cefoxitin 2 gm IV q6-8h
OR
Imipenem 0.5 gm IV q6h
OR
Piperacillin Tazobactam 3.375 gm IV q6h (or 4-hour infusion of 3.375 gm q8h)
OR
Ampicillin Sulbactam 3 gm IV q6h

References

Template:WH Template:WS